Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2021 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported...
September 23, 2021 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support...
August 04, 2021 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the...
June 29, 2021 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737

HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
June 22, 2021 07:30 ET | Source: vTv Therapeutics Inc.; Cantex Pharmaceuticals, Inc.

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered...
May 05, 2021 16:10 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of...
April 13, 2021 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
April 12, 2021 16:30 ET | Source: vTv Therapeutics Inc.

TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
March 23, 2021 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399

HIGH POINT, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods...
March 18, 2021 16:05 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...